Table of Contents
Cells, Volume 7, Issue 9 (September 2018)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) IKKβ has been the historical focus of drug development pipelines aimed at inhibiting canonical [...] Read more. IKKβ has been the historical focus of drug development pipelines aimed at inhibiting canonical NF-κB activity. However, to date, no IKKβ inhibitors have been clinically approved. This review will outline the latest efforts to design highly selective IKKβ inhibitors. With a focus on cancer therapy, we will also discuss possible reasons for their lack of clinical success, the current barriers to clinical approval, recent opportunities for their therapeutic utilization, and alternate strategies to inhibit NF-κB activity that may prove more tractable than direct IKKβ inhibition. View this paper.